You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

New Integrase Strand Transfer Inhibitor Approved To Treat HIV-1

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000438862.37283.a8
Drug Watch
Abstract

* A new drug, Dolutegravir (Tivicay), has been approved to treat HIV-1 infection in both treatment-naïve patients and those who have received prior therapy against HIV infection.

* Possible serious adverse effects of the drug include hypersensitivity and abnormal liver function if the patient is coinfected with hepatitis B or hepatitis C.

Author Information

Diane S. Aschenbrenner recently retired as course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: daschen1@jhu.edu.

© 2013 Lippincott Williams & Wilkins. All rights reserved.